VLX600

CAS No. 327031-55-0

VLX600( —— )

Catalog No. M21963 CAS No. 327031-55-0

VLX600 is an iron-chelating oxidative phosphorylation (OXPHOS) inhibitor, is a cell-permeable anticancer agent.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 43 Get Quote
10MG 69 Get Quote
25MG 142 Get Quote
50MG 237 Get Quote
100MG 405 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    VLX600
  • Note
    Research use only, not for human use.
  • Brief Description
    VLX600 is an iron-chelating oxidative phosphorylation (OXPHOS) inhibitor, is a cell-permeable anticancer agent.
  • Description
    VLX600 is an iron-chelating oxidative phosphorylation (OXPHOS) inhibitor, is a cell-permeable anticancer agent.?It acts by reducing mitochondrial oxidative phosphorylation in tumor cells.VLX600 as a drug that is preferentially active against quiescent cells in colon cancer 3-D microtissues.?The anticancer activity is associated with reduced mitochondrial respiration, leading to bioenergetic catastrophe and tumour cell death.?VLX600 shows enhanced cytotoxic activity under conditions of nutrient starvation.?Importantly, VLX600 displays tumour growth inhibition in vivo.?(In Vivo):VLX600 (16?mg/kg; i.v.; every third day for 16 days) shows anti-tumor activity in human tumor xenografts.
  • In Vitro
    VLX600 (6?μM; 72 hours) induces an autophagic response.VLX600 is cytotoxic to HCT116 spheroids. VLX600 induces a HIF-1α-dependent glycolytic response. VLX600 inhibits oxygen consumption in HCT116 cells. VLX600 inhibits phosphorylation of the mTOR downstream effectors 4EBP1 and p70-S6K by an HIF-1α-independent mechanism. VLX600 preferentially leads to decreased ATP levels in cancer but not normal cells.Cell Proliferation Assay Cell Line:HCT116, HT29, SW620, HT8, DLD and RKO cells Concentration:0.1, 1, 10, 100μM Incubation Time:72 hours Result:Inhibited the proliferation of these cells.Western Blot Analysis Cell Line:HCT116 cells Concentration:6?μM Incubation Time:72?hoursResult:LC3-II was induced.
  • In Vivo
    VLX600 (16?mg/kg; i.v.; every third day for 16 days) shows anti-tumor activity in human tumor xenografts. Animal Model:NMRI nu/nu mice (HCT116 and HT29 colon cancer xenografts)Dosage:16?mg/kg Administration:Intravenously; every third day for 16 days Result:Anti-tumor activity was observed in both HCT116 and HT29 colon cancer xenografts.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    oxidative phosphorylation (OXPHOS)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    327031-55-0
  • Formula Weight
    317.35
  • Molecular Formula
    C17H15N7
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:8 mg/ml(25.21 mM)
  • SMILES
    C\C(=N/Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Xiaonan Zhang , M?rten Frykn?s , Emma Hernlund,et al. Induction of Mitochondrial Dysfunction as a Strategy for Targeting Tumour Cells in Metabolically Compromised Microenvironments[J].Nat Commun. 2014;5:3295.2. Karlsson H, et al. A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation. Oncotarget. 2019 Sep 3;10(51):5372-5382.3. Arun Kanakkanthara , Kiran Kurmi , Thomas L Ekstrom, et al.BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents[1].Cancer Res. 2019 Dec 1;79(23):5920-5929.
molnova catalog
related products
  • D-Asparagine

    D-Asparagine is a source of nitrogen for yeast strains. D-Asparagine is a competitive inhibitor of L-Asparagine hydrolysis (Ki = 0.24 mM).

  • Fibrinopeptide A, hu...

    Fibrinopeptide A, human is a 16-residue short polypeptide cleaved from fibrinogen by thrombin. Fibrinopeptide A, human locates at the NH2-termini of the Aα chain.The conversion of monomeric fibrinogen into polymeric fibrin is mediated by thrombin, which binds to the central region of fibrinogen and catalyzes cleavage of the 2 short peptides, the 16-residue fibrinopeptide A (FpA) and the 14-residue fibrinopeptide B (FpB), located at the NH2-termini of the Aα and Bβ chains, respectively.

  • Tamerit

    Tamerit as an efficient inhibitor of oxidative burst in monocytes.